An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 389(10068): 528-537, 2017 02 04.
Article
em En
| MEDLINE
| ID: mdl-28012564
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Metotrexato
/
Imunossupressores
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Observational_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article